Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Form 8-K on March 13, 2026, reporting an event that occurred on March 10, 2026. The company is listed on The Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial data. Revenue, profit, cash flow, margins, debt, and liquidity metrics are not reported in this document.
Material Changes
The filing reports the passing of Dr. Anthony Japour, a member of the Company's board of directors, on March 10, 2026.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies beyond the reported departure of a director.
Investor Verification Checklist
- Verify the status of the Board of Directors following the passing of Dr. Anthony Japour.
- Check for subsequent filings regarding the appointment of a replacement director.
- Review the company's most recent 10-K or 10-Q for current financial health, as this 8-K contains no financial data.